Results 201 to 210 of about 134,446 (292)

Peptide‐directed nanovehicles enabling tumor‐selective ROS amplification and antitumor immunity

VIEW, EarlyView.
Cancer cells are vulnerable to oxidative stress, yet exploit immune tolerance to escape destruction. In contrast, their metabolic profile is markedly altered to support rapid proliferation, accompanied by elevated production of reactive oxygen species (ROS).
Manuela Calin, Galyna Bila, Ileana Manduteanu, Rostyslav Bilyy   +3 more
wiley   +1 more source

Nanobodies as next‐generation targeting platforms: From discovery technologies to translational biomedicine

VIEW, EarlyView.
Nanobodies, derived from the variable domains of camelid heavy‐chain‐only antibodies, have emerged as transformative biomedical tools due to their nanoscale size, exceptional stability, and unique capacity to recognize cryptic epitopes. This review provides a comprehensive overview of the field, outlining the structural and biochemical features of ...
Zhenrui Ye, Xianyang Li, Meixiao Zhan
wiley   +1 more source

Nanomedicine applications in lymphoma: Advancing precision diagnostics, targeted therapeutics, and prospective developments

VIEW, EarlyView.
Lymphoma is a group of blood cancers that can appear in lymph nodes, blood, bone marrow, spleen, liver, or the central nervous system, which makes drug delivery and disease monitoring difficult. This review summarizes how nanomedicine technologies may improve targeted treatment and imaging, while carefully separating approved or guideline‐supported ...
Mohd Ahmar Rauf, Yara Mashal, Afeefa Rao, Nasar Ata, Arun K. Iyer, Farhan Shah   +5 more
wiley   +1 more source

Impact of CD38 Deficiency on B Cell Development in CD19-Deficient Mice. [PDF]

Scand J Immunol
Abrego-Peredo A, Gallardo-Hernández CA, López-Herrera G, Romero-Ramírez H, García-García F, Pineda-Olvera B, Rodríguez-Alba JC.   +6 more
europepmc   +1 more source

Angiogenesis‐associated immune genes as prognostic markers and predictors of immunotherapy response in pancreatic ductal adenocarcinoma

VIEW, EarlyView.
Pancreatic ductal adenocarcinoma exhibits marked angiogenic and immune heterogeneity. We identified 28 angiogenesis‐associated immune genes and developed a seven‐gene AIGScore model comprising FGF2, ADGRB3, MMP2, TYMP, VASH1, VEGFD, and ITGAV. A high AIGScore was associated with poor survival, an immunosuppressive tumor microenvironment, and reduced ...
Qing Chang, Qian Wang, Xiumei Jiang, Yongmei Yang, Ailin Qu   +4 more
wiley   +1 more source

Monoclonal Antibody CD19 [PDF]

, 2020
openaire   +1 more source

Novel Bispecific Engagers Targeting the CεmX Domain of mIgE‐Expressing Cells

Allergy, EarlyView.
We developed bispecific TCE & NKCE targeting the CεmX domain of mIgE to eliminate IgE‐producing cells. Both constructs demonstrated potent, specific, dose‐dependent cytotoxicity and selective immune activation in vitro. These results highlight their promise as off‐the‐shelf, potentially curative therapeutics for IgE‐associated allergic diseases ...
Constantin Möller, Julia Hambach, Alessa Zoe Schaffrath, Thomas Eden, Sophia Cichutek, Anna Josephine Gebhardt, Natalie Tode, Ronald Maitschke‐Rajasekharan, Philipp Lewe, Sharon Qi, Susanne Witt, Marie Eggers, Nicola M. Tomas, Friedrich Haag, Friedrich Koch‐Nolte, Boris Fehse, Kristoffer Riecken   +16 more
wiley   +1 more source

Increased Frequency of the Chemokine Receptor CCR2 on Circulating CD19+CD5+ Lymphocytes in Therapy-Naïve CLL Patients With the Detectable EBV DNA and High-Avidity Antibodies Against the EBV Capsid Antigen. [PDF]

Can J Infect Dis Med Microbiol
Zvejniece L, Kozireva S, Nazarenko M, Kornilova O, Rivkina A, Lejniece S, Leonciks A, Murovska M, Kashuba E, Kholodnyuk I.   +9 more
europepmc   +1 more source

Autosomal Dominant Hyper‐IgE Syndrome Patients Retain IL10‐Producing preTh17‐Cells That Are Activated by Opportunistic Pathogens and Support IgE Production

Allergy, EarlyView.
IL‐10 producing CCR6+Th‐cells are central memory T‐cells that express ROR‐γt and differentiate to Th17‐cells via an autocrine loop of STAT3‐activating cytokines (preTh17). STAT3‐deficient AD‐HIES patients lack Th17‐ and Tfh17‐cells but retain preTh17‐ and Th1/17‐cells.
Giorgia Moschetti, Chiara Vasco, Francesca Clemente, Paola Larghi, Sara Maioli, Edoardo Scarpa, Elena Carelli, Nadia Pulvirenti, Maria Lucia Sarnicola, Mariacristina Crosti, Manal Bel Imam, Willem van de Veen, Loris Rizzello, Sergio Abrignani, Lucia A. Baselli, Rosa Maria Dellepiane, Maria Carrabba, Giovanna Fabio, Jens Geginat   +18 more
wiley   +1 more source